Macrophages as a source of HIV during opportunistic infections.

Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 9.11

Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J Virol (2000) 3.48

Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice. Proc Natl Acad Sci U S A (2006) 3.07

Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A (2001) 2.96

Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood (2008) 2.96

Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev (2001) 2.87

Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med (2006) 2.83

Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis. J Virol (2001) 2.67

Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol (2002) 2.59

Tuberculosis and HIV co-infection. PLoS Pathog (2012) 2.57

Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res (2008) 2.40

The prolonged life-span of alveolar macrophages. Am J Respir Cell Mol Biol (2008) 2.16

Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J Exp Med (2004) 2.05

Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med (1999) 1.96

Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood (2007) 1.93

Macrophages in vaginal but not intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1 infection. J Virol (2009) 1.84

Multiple modes of cellular activation and virus transmission in HIV infection: a role for chronically and latently infected cells in sustaining viral replication. Proc Natl Acad Sci U S A (1998) 1.80

Intestinal macrophages and response to microbial encroachment. Mucosal Immunol (2010) 1.76

Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 1.68

Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol (2001) 1.67

Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates. J Virol (1999) 1.66

Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood (2011) 1.62

The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol (2009) 1.55

Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology (2010) 1.51

Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J Virol (2006) 1.47

Dendritic cell-T-cell interactions support coreceptor-independent human immunodeficiency virus type 1 transmission in the human genital tract. J Virol (1999) 1.46

Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation. Retrovirology (2015) 1.43

Maximal HIV-1 replication in alveolar macrophages during tuberculosis requires both lymphocyte contact and cytokines. J Exp Med (2002) 1.43

HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One (2009) 1.42

Macrophages and their relevance in Human Immunodeficiency Virus Type I infection. Retrovirology (2012) 1.41

Type I interferon induces inhibitory 16-kD CCAAT/ enhancer binding protein (C/EBP)beta, repressing the HIV-1 long terminal repeat in macrophages: pulmonary tuberculosis alters C/EBP expression, enhancing HIV-1 replication. J Exp Med (1998) 1.41

Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol (2011) 1.38

Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation. J Virol (2005) 1.37

Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology (2010) 1.36

Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology (2010) 1.33

Susceptibility of rat-derived cells to replication by human immunodeficiency virus type 1. J Virol (2001) 1.33

p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway. Proc Natl Acad Sci U S A (2013) 1.31

The CDK inhibitor p21Cip1/WAF1 is induced by FcgammaR activation and restricts the replication of human immunodeficiency virus type 1 and related primate lentiviruses in human macrophages. J Virol (2009) 1.30

Macrophage-tropic simian/human immunodeficiency virus chimeras use CXCR4, not CCR5, for infections of rhesus macaque peripheral blood mononuclear cells and alveolar macrophages. J Virol (2003) 1.29

Transient induction of cyclin T1 during human macrophage differentiation regulates human immunodeficiency virus type 1 Tat transactivation function. J Virol (2002) 1.29

Potential role for CD63 in CCR5-mediated human immunodeficiency virus type 1 infection of macrophages. J Virol (2003) 1.28

Epidemiology, genetic diversity, and evolution of endemic feline immunodeficiency virus in a population of wild cougars. J Virol (2003) 1.27

Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J Virol (2008) 1.27

Interleukin-27 inhibition of HIV-1 involves an intermediate induction of type I interferon. Blood (2009) 1.23

Novel nuclear import of Vpr promoted by importin alpha is crucial for human immunodeficiency virus type 1 replication in macrophages. J Virol (2007) 1.23

Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J Exp Med (2002) 1.23

Interleukin-10 promoter polymorphisms influence HIV-1 susceptibility and primary HIV-1 pathogenesis. J Infect Dis (2009) 1.21

Role of p38 mitogen-activated protein kinase in HIV type 1 production in vitro. Proc Natl Acad Sci U S A (1998) 1.21

Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance. J Immunol (2009) 1.20

Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239. J Virol (2005) 1.17

Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. Retrovirology (2009) 1.17

Alpha/beta interferon impairs the ability of human macrophages to control growth of Mycobacterium bovis BCG. Infect Immun (2002) 1.17

Cytokine regulation of human immunodeficiency virus type 1 entry and replication in human monocytes/macrophages through modulation of CCR5 expression. J Virol (1998) 1.16

Cellular compartments of human immunodeficiency virus type 1 replication in vivo: determination by presence of virion-associated host proteins and impact of opportunistic infection. J Virol (2000) 1.15

APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J Virol (2012) 1.14

Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection. J Virol (2004) 1.11

Nerve growth factor is an autocrine factor essential for the survival of macrophages infected with HIV. Proc Natl Acad Sci U S A (1999) 1.08

Inhibition of anti-HIV microRNA expression: a mechanism for opioid-mediated enhancement of HIV infection of monocytes. Am J Pathol (2010) 1.08

Extensive HIV-1 intra-host recombination is common in tissues with abnormal histopathology. PLoS One (2009) 1.08

Eradication of HIV-1 from the macrophage reservoir: an uncertain goal? Viruses (2015) 1.07

CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques. Proc Natl Acad Sci U S A (2003) 1.07

Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic. Proc Natl Acad Sci U S A (2002) 1.07

CD4+ T cell depletion in human immunodeficiency virus (HIV) infection: role of apoptosis. Viruses (2011) 1.07

Interleukin-10 induces inhibitory C/EBPbeta through STAT-3 and represses HIV-1 transcription in macrophages. Am J Respir Cell Mol Biol (2005) 1.06

Elevated serum concentrations of soluble CD14 in HIV- and HIV+ patients with tuberculosis in Africa: prolonged elevation during anti-tuberculosis treatment. Clin Exp Immunol (2000) 1.05

HIV-1 infection induces changes in expression of cellular splicing factors that regulate alternative viral splicing and virus production in macrophages. Retrovirology (2008) 1.05

Primary CD8+ cells from HIV-infected individuals can suppress productive infection of macrophages independent of beta-chemokines. Proc Natl Acad Sci U S A (1998) 1.03

Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression. Proc Natl Acad Sci U S A (1998) 1.02

Estradiol reduces susceptibility of CD4+ T cells and macrophages to HIV-infection. PLoS One (2013) 1.01

Exposure to bacterial products renders macrophages highly susceptible to T-tropic HIV-1. J Clin Invest (1998) 1.01

Genetic analyses of HIV-1 env sequences demonstrate limited compartmentalization in breast milk and suggest viral replication within the breast that increases with mastitis. J Virol (2010) 1.00

The engagement of activating FcgammaRs inhibits primate lentivirus replication in human macrophages. J Immunol (2006) 1.00

Inadequate clearance of translocated bacterial products in HIV-infected humanized mice. PLoS Pathog (2010) 1.00

Eradication therapies for HIV Infection: time to begin again. AIDS Res Hum Retroviruses (2011) 0.99

Tissue-resident macrophages are productively infected ex vivo by primary X4 isolates of human immunodeficiency virus type 1. J Virol (2005) 0.99

Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors. J Virol (2011) 0.99

Tissue myeloid cells in SIV-infected primates acquire viral DNA through phagocytosis of infected T cells. Immunity (2014) 0.99

Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages. J Virol (2007) 0.98

CSF-induced and HIV-1-mediated distinct regulation of Hck and C/EBPbeta represent a heterogeneous susceptibility of monocyte-derived macrophages to M-tropic HIV-1 infection. J Exp Med (2003) 0.98

Fcgamma receptor-mediated suppression of human immunodeficiency virus type 1 replication in primary human macrophages. J Virol (2003) 0.97

Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol Med (2012) 0.96

Purinergic receptors are required for HIV-1 infection of primary human macrophages. J Immunol (2012) 0.96

Inhibition of HIV-1 replication in primary human monocytes by the IkappaB-alphaS32/36A repressor of NF-kappaB. Retrovirology (2004) 0.96

Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Côte d'Ivoire. Clin Exp Immunol (2005) 0.96

HIV-1 and bacterial pneumonia in the era of antiretroviral therapy. Proc Am Thorac Soc (2011) 0.95

Transcriptional activation of HIV by Mycobacterium tuberculosis in human monocytes. Clin Exp Immunol (1999) 0.95

HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites. HIV AIDS (Auckl) (2010) 0.94

Human immunodeficiency virus type 1 induction mediated by genistein is linked to cell cycle arrest in G2. J Virol (1998) 0.94

HIV and SIV infection: the role of cellular restriction and immune responses in viral replication and pathogenesis. APMIS (2009) 0.94

Interferon block to HIV-1 transduction in macrophages despite SAMHD1 degradation and high deoxynucleoside triphosphates supply. Retrovirology (2013) 0.94

Dynamics of HIV-containing compartments in macrophages reveal sequestration of virions and transient surface connections. PLoS One (2013) 0.94

HIV infection enhances TRAIL-induced cell death in macrophage by down-regulating decoy receptor expression and generation of reactive oxygen species. PLoS One (2011) 0.93

Incidence of multiple Herpesvirus infection in HIV seropositive patients, a big concern for Eastern Indian scenario. Virol J (2010) 0.93

Protein kinase C-delta regulates HIV-1 replication at an early post-entry step in macrophages. Retrovirology (2012) 0.92

Stromal down-regulation of macrophage CD4/CCR5 expression and NF-κB activation mediates HIV-1 non-permissiveness in intestinal macrophages. PLoS Pathog (2011) 0.92

Effects of HIV-1 infection in vitro on transendothelial migration by monocytes and monocyte-derived macrophages. J Leukoc Biol (2009) 0.90

Roles of Vpr and Vpx in modulating the virus-host cell relationship. Mol Aspects Med (2010) 0.90

Surfactant protein A modulates the inflammatory response in macrophages during tuberculosis. Infect Immun (2004) 0.90

HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses (2014) 0.89

The role of infection in miscarriage. Hum Reprod Update (2015) 0.89

N-formylmethionyl peptides as chemoattractants for leucocytes. Proc Natl Acad Sci U S A (1975) 9.24

Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A (1987) 6.43

Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ (2008) 6.23

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med (1995) 5.69

Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol (1999) 5.58

Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med (1998) 3.56

Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). I. Characterization of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions by flow cytometric analysis. Cell Immunol (1984) 3.36

TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity (2001) 3.20

Lymphocyte-mediated activation of fibroblast proliferation and collagen production. J Immunol (1978) 3.16

Collagenase production by endotoxin-activated macrophages. Proc Natl Acad Sci U S A (1974) 3.05

Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa. J Exp Med (1992) 3.03

Soluble surface proteins from Helicobacter pylori activate monocytes/macrophages by lipopolysaccharide-independent mechanism. J Clin Invest (1991) 3.00

Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med (1993) 2.98

Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest (1995) 2.95

Pupillary signs in diabetic autonomic neuropathy. Br Med J (1978) 2.79

Collagenase production by lymphokine-activated macrophages. Science (1975) 2.64

Inflammatory and immunomodulatory roles of TGF-beta. Immunol Today (1989) 2.56

Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med (2000) 2.48

Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood (1997) 2.41

Macrophage activation by mycobacterial water soluble compounds and synthetic muramyl dipeptide. J Immunol (1979) 2.39

Lipopolysaccharide, tumor necrosis factor-alpha, and IL-1 beta prevent programmed cell death (apoptosis) in human peripheral blood monocytes. J Immunol (1991) 2.39

Role of a peptidase in phagocyte chemotaxis. Proc Natl Acad Sci U S A (1976) 2.38

Lord Bradley's review of people with mental health or learning disabilities in the criminal justice system in England: All not equal in the eyes of the law? Int J Prison Health (2009) 2.33

Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines. J Immunol (1991) 2.23

Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta. J Exp Med (1990) 2.19

Transforming growth factor beta 1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest (1991) 2.18

Association of circulating receptor Fc gamma RIII-positive monocytes in AIDS patients with elevated levels of transforming growth factor-beta. J Clin Invest (1991) 2.11

Monocyte function in the acquired immune deficiency syndrome. Defective chemotaxis. J Clin Invest (1984) 2.10

Transforming growth factor beta: a matter of life and death. J Leukoc Biol (1994) 1.97

Theatre air sampling--ignorance is bliss! J Hosp Infect (1995) 1.91

The pathogenesis of group A streptococcal cell wall-induced polyarthritis in the rat. Comparative studies in arthritis resistant and susceptible inbred rat strains. Arthritis Rheum (1983) 1.83

Requirement for transforming growth factor beta1 in controlling T cell apoptosis. J Exp Med (2001) 1.82

Purification and determination of the structure of capsular polysaccharide of Vibrio vulnificus M06-24. J Bacteriol (1992) 1.81

Candida albicans in patients with the acquired immunodeficiency syndrome: absence of a novel of hypervirulent strain. J Infect Dis (1990) 1.77

Community-based asthma care: trial of a "credit card" asthma self-management plan. Eur Respir J (1994) 1.76

Intestinal macrophages and response to microbial encroachment. Mucosal Immunol (2010) 1.76

Role of the thymus in streptococcal cell wall-induced arthritis and hepatic granuloma formation. Comparative studies of pathology and cell wall distribution in athymic and euthymic rats. J Clin Invest (1985) 1.73

Topical estrogen accelerates cutaneous wound healing in aged humans associated with an altered inflammatory response. Am J Pathol (1999) 1.70

Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest (1997) 1.67

NIH conference. Rheumatoid arthritis: evolving concepts of pathogenesis and treatment. Ann Intern Med (1984) 1.61

Macrophage production of fibronectin, a chemoattractant for fibroblasts. J Immunol (1981) 1.58

Daily energy expenditure in Mexican and USA Pima indians: low physical activity as a possible cause of obesity. Int J Obes Relat Metab Disord (2000) 1.55

Induction of guinea pig B-cell lymphokine synthesis by mitogenic and nonmitogenic signals to Fc, Ig, and C3 receptors. J Exp Med (1974) 1.53

Fas mediates apoptosis in human monocytes by a reactive oxygen intermediate dependent pathway. J Immunol (1996) 1.51

Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J Exp Med (1999) 1.49

In vitro studies of a chemotactic lymphokine in the guinea pig. Int Arch Allergy Appl Immunol (1974) 1.46

Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. Blood (1990) 1.42

Monocyte interleukin 2 receptor gene expression and interleukin 2 augmentation of microbicidal activity. J Immunol (1987) 1.40

Modulation of fibroblast growth by a lymphokine of human T cell continuous T cell line origin. J Immunol (1983) 1.39

Standard effective doses for proliferative tumours. Phys Med Biol (1999) 1.39

Type I transforming growth factor-beta receptors on neutrophils mediate chemotaxis to transforming growth factor-beta. J Immunol (1991) 1.33

Lethal effects of Actinobacillus actinomycetemcomitans leukotoxin on human T lymphocytes. Infect Immun (1991) 1.32

Gonococcal infection within Scotland: antigenic heterogeneity and antibiotic susceptibility of infecting strains. Eur J Epidemiol (1990) 1.31

Malignancy and mortality in a population-based cohort of patients with coeliac disease or "gluten sensitivity". World J Gastroenterol (2007) 1.30

The role of macrophages in the production of lymphokines by T and B lymphocytes. J Immunol (1975) 1.29

Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson's disease: a comparison with untreated patients and normal age-matched controls. Mov Disord (2001) 1.29

T lymphocyte-dependent evolution of bacterial cell wall-induced hepatic granulomas. J Immunol (1986) 1.29

Apoptosis in human monocytes: possible role in chronic inflammatory diseases. J Periodontol (1993) 1.26

Hepatic fibrosis in schistosomiasis: egg granulomas secrete fibroblast stimulating factor in vitro. Science (1978) 1.25

Inhibition by cyclosporin A of streptococcal cell wall-induced arthritis and hepatic granulomas in rats. Arthritis Rheum (1986) 1.25

Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients. J Antimicrob Chemother (1986) 1.24

Cytomegalovirus induction of tumor necrosis factor-alpha by human monocytes and mucosal macrophages. J Clin Invest (1992) 1.24

The role of the oral environment in HIV-1 transmission. J Am Dent Assoc (1998) 1.24

IL-4 enhances programmed cell death (apoptosis) in stimulated human monocytes. J Immunol (1992) 1.24

Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor beta 1 knockout mice. Proc Natl Acad Sci U S A (1994) 1.23

Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. J Immunol (1993) 1.23

Isolation of human mononuclear cell subsets by counterflow centrifugal elutriation (CCE). II. Functional properties of B-lymphocyte-, T-lymphocyte-, and monocyte-enriched fractions. Cell Immunol (1984) 1.22

Selective induction of Fc gamma RIII on human monocytes by transforming growth factor-beta. J Immunol (1990) 1.22

Modification of forearm resistance vessels by exercise training in young men. J Appl Physiol (1985) (1994) 1.21

Spontaneous production of fibroblast-activating factor(s) by synovial inflammatory cells. A potential mechanism for enhanced tissue destruction. J Exp Med (1985) 1.20

Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans. J Infect Dis (1990) 1.18

Lymph node architecture preceding and following 6 months of potent antiviral therapy: follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patient. AIDS (1999) 1.18

Substance P receptor-mediated chemotaxis of human monocytes. Peptides (1985) 1.18

Complement-induced histamine release from human basophils. I. Generation of activity in human serum. J Immunol (1975) 1.17

Co-expression of chemotactic ligand receptors on human peripheral blood monocytes. J Immunol (1987) 1.16

Fibroblast stimulation in schistosomiasis. I. Stimulation in vitro of fibroblasts by soluble products of egg granulomas. J Infect Dis (1981) 1.16

Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes (2006) 1.15

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer (2011) 1.15

Induction of alpha interferon by human immunodeficiency virus type 1 in human monocyte-macrophage cultures. J Virol (1991) 1.14

Stroke in Devon: knowledge was good, but action was poor. J Neurol Neurosurg Psychiatry (2004) 1.12

Immune function in severe, active rheumatoid arthritis. A relationship between peripheral blood mononuclear cell proliferation to soluble antigens and synovial tissue immunohistologic characteristics. J Clin Invest (1984) 1.11

Benzodiazepine receptor-mediated chemotaxis of human monocytes. Science (1985) 1.10

Experience with a trigger tool for identifying adverse drug events among older adults in ambulatory primary care. Qual Saf Health Care (2009) 1.10

Anti-CD45RB/anti-TIM-1-induced tolerance requires regulatory B cells. Am J Transplant (2012) 1.10

Oral delivery of group A streptococcal cell walls augments circulating TGF-beta and suppresses streptococcal cell wall arthritis. J Immunol (1998) 1.10

Access to health care for the rural elderly. JAMA (2000) 1.09

Partial IgA-deficiency with increased Th2-type cytokines in TGF-beta 1 knockout mice. J Immunol (1999) 1.08

Cytokines and neuropathology. Trends Pharmacol Sci (1992) 1.07

A comparison of six different plating media used in the isolation of Salmonella. Int J Food Microbiol (1994) 1.06

Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland. Br J Cancer (2009) 1.06

Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages. Proc Natl Acad Sci U S A (1989) 1.05

Expression of interleukin 2 receptors by monocytes from patients with acquired immunodeficiency syndrome and induction of monocyte interleukin 2 receptors by human immunodeficiency virus in vitro. J Clin Invest (1990) 1.04

Humoral recall responses in HIV infection. Levels, specificity, and affinity of antigen-specific IgG. J Immunol (1991) 1.04

Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis (2008) 1.03

A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc Natl Acad Sci U S A (1992) 1.03

Inhibition of in vitro lymphokine synthesis by glucocorticosteroids. J Immunol (1975) 1.03

Leukapheresis in rheumatoid arthritis. Association of clinical improvement with reversal of anergy. Arthritis Rheum (1983) 1.03

Plasmid DNA encoding transforming growth factor-beta1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model. J Clin Invest (1998) 1.03

Cytokines and fibrosis. Clin Exp Rheumatol (1987) 1.03

Differential regulation of colony-stimulating factors and interleukin 2 production by cyclosporin A. Proc Natl Acad Sci U S A (1987) 1.02